iShares MSCI South Korea ETF vs FMC Corp — how do they compare? iShares MSCI South Korea ETF trades at $162.77, while FMC Corp trades at $11.32 (market cap $1.36B). The key difference: FMC Corp pays a 2.95% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, FMC Corp nearer its low. Which is the better fit depends on your goals.
| EWY | FMC | |
|---|---|---|
Sector | Broad Market / Factor | Basic Materials |
52-Week High | $219.20 | $43.90 |
52-Week Low | $70.65 | $10.72 |
Market Cap | — | $1.36B |
Enterprise Value | — | $5.50B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $163.67, down 7.52% with significant volatility driven by its heavy concentration in South Korean semiconductor giants Samsung and SK Hynix. The ETF has entered bear market territory, reflecting global tech sector pressures and foreign investor selling. Technical indicators show bearish momentum with RSI near oversold levels at 28, while support sits at $157. Recent news highlights the Kospi Index's 21% decline from YTD highs, creating both risk and potential opportunity.
The outlook remains challenged by semiconductor cycle volatility and concentrated exposure, but long-term AI demand fundamentals provide potential upside. Key risks include single-stock concentration, foreign capital flows, and global tech sentiment shifts. Investors should weigh near-term volatility against structural semiconductor growth drivers.
FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.
The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.
Trailing returns across standard periods
Latest headlines on both assets
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →